Bispecific antibody · Immune activation, directed at CD3 (CD3E) and HIV-1 envelope glycoprotein gp41 subunit · developed by MacroGenics
MGD020 is a bispecific DART molecule that binds CD3 and the gp41 subunit of the HIV-1 envelope. It is being studied in human immunodeficiency virus type 1 infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05261191 | Phase 1 | Human Immunodeficiency Virus I Infection | Completed | MGNX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Human Immunodeficiency Virus I InfectionHuman Immunodeficiency Virus Type 1Immunodeficiency Virus Type 1, Human
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.
See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGNX catalysts and pipeline →